MDLN - Medline Inc.

MDLN Securities Alert: Lose Money on Your Medline Investment? BFA Law Notifies Investors of the Ongoing Securities Fraud Investigation over Product Quality Issues

NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

Oct 09, 2026 02:33 AM • globenewswire.com

MDLN ALERT: Kaplan Fox & Kilsheimer LLP is Investigating Medline Inc. (MDLN) for Potential Securities Law Violations

New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Oct 08, 2026 01:35 PM • newsfilecorp.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Oct 08, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

Medline (NASDAQ:MDLN) Stock: Insider Private Ltd Gic Sells 2,570,999 Shares

Medline (NASDAQ: MDLN - Get Free Report) major shareholder Private Ltd Gic sold 2,570,999 shares of the company's stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the sale, the insider owned 20,231,483 shares in

Oct 07, 2026 03:38 AM • defenseworld.net

MDLN Investor Reminder: BFA Law Reminds Medline Investors that Lost Money when Stock Dropped 13% of the Ongoing Securities Fraud Investigation

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

Oct 07, 2026 02:18 AM • globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Oct 06, 2026 03:41 PM • globenewswire.com (Hide legal announcements)

Kaplan Fox is Investigating Medline Inc. (MDLN) for Investors Who Suffered Losses

New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Oct 06, 2026 12:50 PM • newsfilecorp.com

MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 12.8% Share Drop

NEW YORK--(BUSINESS WIRE)---- $MDLN #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On June 2, 2026, the FDA published a warning letter that detailed Medline's “significant violations of Curr.

Oct 06, 2026 06:00 AM • businesswire.com (Hide legal announcements)

Medline to report third quarter 2026 results on November 4, 2026

NORTHFIELD, Ill., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report third quarter 2026 financial results on Wednesday, November 4, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results.

Oct 06, 2026 05:00 AM • globenewswire.com

MDLN Stock Notice: Medline Stock Plummeted 13% after Product Quality Issues Disclosed - Securities Fraud Investigation Underway

MDLN Stock Notice: Medline Stock Plummeted 13% after Product Quality Issues Disclosed - Securities Fraud Investigation UnderwayPR NewswireNEW YORK, Oct. 6, 2026

Oct 06, 2026 02:00 AM • gurufocus.com

MDLN Stock Notice: Medline Stock Plummeted 13% after Product Quality Issues Disclosed - Securities Fraud Investigation Underway

BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP  announces an investigation into Medline Inc. (NASDAQ: MDLN) for potential securities fraud after its significant stock drops.

Oct 06, 2026 01:36 AM • prnewswire.com

MDLN Investigation Notification: Medline is Under Investigation for Securities Fraud over Product Quality Issues – Contact BFA Law if You Suffered Losses

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

Oct 05, 2026 02:07 AM • globenewswire.com

Kaplan Fox Urges Investors of Medline Inc. (MDLN) with Losses to Contact the Firm

New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Oct 02, 2026 10:00 AM • newsfilecorp.com

$MDLN Shareholder Notice: A Securities Fraud Investigation is Ongoing on behalf of Medline Investors with Losses – Contact BFA Law

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.

Oct 02, 2026 01:36 AM • globenewswire.com

Bragar Eagel & Squire, P.C. is Investigating Medline Inc. on Behalf of Medline Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Medline (MDLN) To Contact Him Directly To Discuss Their Options

Oct 01, 2026 11:58 AM • globenewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Oct 01, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

Kaplan Fox Reminds Investors of Medline Inc. (MDLN) of an Ongoing Securities Investigation

New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us.

Sep 30, 2026 06:05 AM • newsfilecorp.com

$MDLN Investigation Notification: Suffer Losses on Your Medline Investment? BFA Law Reminds Investors of the Ongoing Securities Fraud Investigation

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops.

Sep 30, 2026 02:17 AM • globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Inc. - MDLN

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Sep 29, 2026 01:45 PM • globenewswire.com (Hide legal announcements)

Medline Legal Alert: Medline (MDLN) Investors who Lost Money are Notified of the Ongoing Securities Fraud Investigation

BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Sept.

Sep 29, 2026 02:05 AM • prnewswire.com

Medline price target lowered to $43 from $45 at Barclays

$43.00 (was $35.74)

Barclays

Oct 09, 2026 05:34 AM • TheFly

Medline price target lowered to $43 from $45 at UBS

$43.00 (was $34.80)

Kevin Caliendo · UBS

Sep 25, 2026 09:22 AM • TheFly

BTIG Reiterates Buy Rating on Medline Inc (MDLN)

$55.00 (was $34.58)

David Larsen · BTIG

Aug 27, 2026 05:09 AM • StreetInsider

Medline price target lowered to $42 from $45 at Bairdq

$42.00 (was $35.30)

Eric Coldwell · Robert W. Baird

Aug 06, 2026 09:23 AM • TheFly

Medline price target lowered to $39 from $48 at Evercore ISI

$39.00 (was $35.71)

Evercore ISI

Aug 06, 2026 08:51 AM • TheFly

Medline price target lowered to $45 from $50 at Stifel

$45.00 (was $35.54)

Stifel Nicolaus

Aug 06, 2026 08:30 AM • TheFly

Medline price target lowered to $47 from $54 at BMO Capital

$47.00 (was $36.66)

Sean Dodge · BMO Capital

Aug 06, 2026 07:31 AM • TheFly

Medline price target lowered to $46 from $53 at RBC Capital

$46.00 (was $36.66)

RBC Capital

Aug 06, 2026 07:05 AM • TheFly

Medline price target lowered to $37 from $42 at Deutsche Bank

$37.00 (was $36.66)

Deutsche Bank

Aug 06, 2026 04:19 AM • TheFly

Medline price target lowered to $45 from $57 at Baird

$45.00 (was $33.19)

Eric Coldwell · Robert W. Baird

Jun 03, 2026 06:39 AM • TheFly

Medline price target lowered to $45 from $50 at Barclays

$45.00 (was $36.56)

Glen Santangelo · Barclays

Jun 01, 2026 06:05 AM • TheFly

Medline price target lowered to $42 from $48 at Deutsche Bank

$42.00 (was $41.95)

Deutsche Bank

May 07, 2026 08:41 AM • TheFly

Medline price target raised to $60 from $55 at Tigress Financial

$60.00 (was $43.41)

Ivan Feinseth · Tigress Financial

Mar 09, 2026 08:03 AM • TheFly

Medline price target raised to $56 from $48 at Leerink

$56.00 (was $48.18)

Michael Cherny · Leerink Partners

Feb 25, 2026 02:48 PM • TheFly

Medline price target raised to $55 from $46 at Stifel

$55.00 (was $48.18)

Stifel Nicolaus

Feb 25, 2026 02:45 PM • TheFly

Medline price target raised to $55 from $50 at Evercore ISI

$55.00 (was $49.38)

Evercore ISI

Feb 25, 2026 01:37 PM • TheFly

Medline initiated with a Buy at Tigress Financial

$55.00 (was $45.01)

Tigress Financial

Feb 05, 2026 09:47 AM • TheFly

Medline price target raised to $55 from $50 at BTIG

$55.00 (was $43.16)

David Larsen · J.P. Morgan

Jan 21, 2026 07:16 AM • TheFly

Medline initiated with an Overweight at Barclays

$50.00 (was $41.65)

Barclays

Jan 12, 2026 08:39 AM • TheFly

Medline initiated with a Neutral at BNP Paribas

$38.00 (was $42.19)

BNP Paribas

Jan 12, 2026 08:17 AM • TheFly